Lung Cancer | Norton Healthcare

Indication: Lung Cancer

A Phase II Multi Center Study of BGB324 in Combination with Pembrolizumab in Patients with Previously Treated Advanced Adenocarcinoma of the Lung

Sub-indication: Adenocarcinoma

Line of Therapy: 1-2 prior lines

Drug Study

Principal Investigator: John Hamm, M.D.
Norton Cancer Institute

Sponsor: BerGenBio ASA

Learn more at ClinicalTrials.gov

Email for more information: Lung-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.